sur INNATE PHARMA (EPA:IPH)
Innate Pharma to Attend Jefferies Global Healthcare Conference
Innate Pharma SA, a biotechnology firm focused on cancer immunotherapies, announced its executive team's participation in the Jefferies Global Healthcare Conference from June 2–4, 2026, in New York. This participation involves direct meetings with investors, providing an opportunity to discuss their latest advances in antibody therapeutics.
Innate Pharma is known for developing cutting-edge treatments like IPH4502 for solid tumors and collaborative efforts with AstraZeneca on non-small cell lung cancer therapies. Their approach centers on unmet medical needs with a focus on innovative antibodies.
This engagement with investors highlights Innate's commitment to fostering relationships within the biotech community and advancing its strategic goals. Innate is publicly traded on Euronext Paris and Nasdaq, underlining its global reach and influence in the healthcare industry.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de INNATE PHARMA